Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 28, 2025Journal of Clinical Pharmacy and TherapeuticsOpen Access

A Real‐World Study of CAR‐T Hematological Adverse Events Based on FAERS Database

View Full Paper
Ask AI
Bookmark
Share

Authors

XGXiaoyue GaoFHFangyuan HuYZYinghong Zhai

Discussion

Loading...

Member takes

Overview

Analysis identifies high rates of hematological adverse events in CAR-T therapy patients, highlighting risks such as cytopenia and hemophagocytic lymphohistiocytosis.

Key Points

  • Hematological adverse events accounted for 11.75% of total adverse events, with cytopenia being notably high.
  • Data from over 47 million reports revealed significant risks including hemophagocytic lymphohistiocytosis and myelodysplastic syndrome.
  • Disproportion analysis methods showed varied hematological events among different CAR-T products, indicating treatment-specific risks.
  • Findings highlight the potential for early identification of serious hematological complications post-CAR-T therapy.

Cite This Study

Gao et al. (2025) studied this question.

synapsesocial.com/papers/6928f12ea65b730b9ea7a725https://doi.org/10.1155/jcpt/5538794
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-World Dermatologic Adverse Events of CAR T-Cell Therapy: A Decade-Wide Disproportionality Analysis of the FDA Adverse Event Reporting System2026
  2. 2Treatment-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Associated with CAR T-Cell Therapies : A Real-World FAERS Pharmacovigilance Study2026
  3. 3Treatment-Related Myelodysplastic Syndrome and Acute Myeloid Leukemia Associated with CAR T-Cell Therapies: A Real-World FAERS Pharmacovigilance Study2026 · 1 citations
  4. 4Comparative cardiovascular and hematologic safety of CAR-T cell therapies and bispecific antibodies: A FAERS-based disproportionality analysis (2022–2024).2025
  5. 5CAR-T therapy pulmonary adverse event profile: a pharmacovigilance study based on FAERS database (2017–2023)2024 · 8 citations